NEWS
Patent granted in India
February 2024
Selentus' patent protecting TenaTac® has been granted in India (patent number 497548).
For further information, please email us at enquiry@selentus.com.
New TenaTac® website launched
October 2023
Selentus is pleased to announce the launch of the new website for its surgical haemostat, TenaTac®. Please visit www.tenatac.com to learn more.
For further information, please email us at enquiry@selentus.com.
Patent granted in Europe
June 2023
Selentus' patent protecting TenaTac® has been granted in Europe (patent number EP 3362110). The patent is also pending in other territories worldwide.
For further information, please email us at enquiry@selentus.com.
Pioneer Group invests in Selentus
December 2022
Selentus is pleased to announce an investment from Pioneer Group to support the development of our surgical haemostat, TenaTac®, an innovative medical device that controls bleeding during a surgical procedure while also reducing the risk of post-operative haemorrhage.
Pioneer Group operates 10 high tech life sciences campuses in the UK and Ireland alongside nationwide accelerator programmes and partnerships with organisations such as Innovate UK. Selentus is based at Pioneer’s BioCity Nottingham site.
“This investment really validates the innovation at Selentus and will assist in the funding of a post-approval clinical study of our lead device, TenaTac®, and the development of an exciting pipeline of new products for surgical bleeding and wound therapy. We have benefited enormously from working in the BioCity, Nottingham life sciences ecosystem and from Pioneer Group’s specialist and dedicated support network. We intend to continue our ambitious growth plans with Pioneer’s support.”
- Ben Nichols, CEO of Selentus
“Our mission is to help life sciences businesses, such as Selentus, thrive at every stage of their innovation journey. We are proud to come in as lead investor in Selentus and strongly believe in the innovation behind TenaTac®, a medical device with an exceptional IP that solves a key gap in the haemostatic market. We are excited to be supporting Selentus’ growth through our investment as well as our all-round incubator programme.”
- Dr. Imelda Juniarsih, Investment Manager at Pioneer Group
For more information, please contact:
Pioneer Group:
Miranda Knaggs
Pioneer Group – Instinctif Partners (Media):
Melanie Toyne-Sewell / Giulia Lasagni / Feyi Ashamu
0207 457 2020
Selentus:
Dr. Ben Nichols, CEO
Patent granted in China
June 2022
Selentus' patent protecting TenaTac® has been granted in China (patent number CN 108136080 B). The patent is also pending in other territories worldwide.
For further information, please email us at enquiry@selentus.com.
December 2021
Patent granted in Brazil
Selentus' patent protecting TenaTac® has been granted in Brazil (patent number BR 112018007612-0 B1). The patent is also pending in other territories worldwide.
For further information, please email us at enquiry@selentus.com.
July 2021
Selentus wins Medilink Innovation Award
Selentus is pleased to announce that it has won the Innovation Award at the Medilink Midlands Business Awards 2021 competition. This award was given for the development of innovative technology that has produced a major improvement in business performance and impacted the market. For further details, please visit: https://www.medilinkem.com/double-winners-at-the-medilink-midlands-business-awards/
For further information, please email us at enquiry@selentus.com.
March 2021
Patent granted in Japan
Selentus' patent protecting TenaTac® has been granted in Japan (patent number JP 6854825). The patent is also pending in many other territories worldwide.
For further information, please email us at enquiry@selentus.com.
Patent granted in U.K.
December 2020
Selentus' patent protecting TenaTac® has been granted in the U.K. (patent number GB 2543307). The patent is also pending in many other territories worldwide.
For further information, please email us at enquiry@selentus.com.
September 2020
Launch of TenaTac® for vets in U.K.
Selentus is pleased to announce the launch of its flagship TenaTac® haemostatic agent for the veterinary market. TenaTac® will be sold to veterinary surgeons in the U.K by Selentus Science.
For further information, please email us at enquiry@selentus.com.
June 2020
Patent granted in U.S.A
Selentus' patent protecting TenaTac® has been granted in the U.S.A. (patent number US 10,653,821). The patent is also pending in many other territories worldwide.
For further information, please email us at enquiry@selentus.com.
TenaTac® approved for sale in Europe
September 2019
Selentus Science Ltd is pleased to report that its partner CuraMedical BV (the Netherlands) has obtained regulatory approval for TenaTac® in the European Union. TenaTac® is an absorbable haemostat with improved tissue adhesion and is indicated for intra-operative surgical bleeding. The product will be marketed in Europe by CuraMedrix BV (the Netherlands). Dr Ben Nichols, Selentus’ Chairman, commented that TenaTac has great potential in the European market and they anticipate further partnerships in North America and Asia-Pacific.
For further information, please email us at enquiry@selentus.com.